Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis.

Böhler C, Radner H, Smolen JS, Aletaha D.

Ann Rheum Dis. 2013 Feb;72(2):241-4. doi: 10.1136/annrheumdis-2012-202297. Epub 2012 Oct 19.

PMID:
23087181
2.

Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study.

Ursum J, Bos WH, van Dillen N, Dijkmans BA, van Schaardenburg D.

Arthritis Res Ther. 2010;12(1):R8. doi: 10.1186/ar2907. Epub 2010 Jan 12.

3.

Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.

Kolarz B, Majdan M, Dryglewska M, Darmochwal-Kolarz D.

Rheumatol Int. 2011 Nov;31(11):1439-43. doi: 10.1007/s00296-010-1509-z. Epub 2010 May 15.

4.

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.

Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.

J Rheumatol. 2008 Oct;35(10):1972-7. Epub 2008 Sep 1.

PMID:
18785316
5.

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.

Klaasen R, Cantaert T, Wijbrandts CA, Teitsma C, Gerlag DM, Out TA, de Nooijer MJ, Baeten D, Tak PP.

Rheumatology (Oxford). 2011 Aug;50(8):1487-93. doi: 10.1093/rheumatology/ker010. Epub 2011 Mar 30.

PMID:
21454308
6.

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.

de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF.

Arthritis Rheum. 2008 May;58(5):1293-8. doi: 10.1002/art.23439.

7.

Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.

Barra L, Bykerk V, Pope JE, Haraoui BP, Hitchon CA, Thorne JC, Keystone EC, Boire G; Catch Investigators.

J Rheumatol. 2013 Aug;40(8):1259-67. doi: 10.3899/jrheum.120736. Epub 2013 Feb 1.

PMID:
23378461
8.

Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.

Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C.

Rheumatol Int. 2015 Oct;35(10):1693-9. doi: 10.1007/s00296-015-3271-8. Epub 2015 Apr 23.

PMID:
25903353
9.

Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.

Joint Bone Spine. 2009 May;76(3):248-53. doi: 10.1016/j.jbspin.2008.09.010. Epub 2009 Feb 8.

PMID:
19208451
10.

Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.

Váncsa A, Szabó Z, Szamosi S, Bodnár N, Végh E, Gergely L, Szucs G, Szántó S, Szekanecz Z.

J Rheumatol. 2013 May;40(5):565-71. doi: 10.3899/jrheum.111488. Epub 2013 Apr 1.

PMID:
23547216
11.
12.

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.

Arthritis Rheum. 2009 Aug;60(8):2232-41. doi: 10.1002/art.24716.

13.

Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.

Shu J, Bykerk VP, Boire G, Haraoui B, Hitchon C, Thorne JC, Tin D, Keystone EC, Pope JE; CATCH Investigators.

J Rheumatol. 2015 Nov;42(11):2023-8. doi: 10.3899/jrheum.150260. Epub 2015 Sep 1.

PMID:
26329342
14.

Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems.

Ursum J, Bos WH, van de Stadt RJ, Dijkmans BA, van Schaardenburg D.

Arthritis Res Ther. 2009;11(3):R75. doi: 10.1186/ar2704. Epub 2009 May 21.

15.

Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.

Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A.

Arthritis Rheumatol. 2016 Jun;68(6):1346-52. doi: 10.1002/art.39595.

16.

Pregnancy mediated improvement of rheumatoid arthritis.

Förger F, Vallbracht I, Helmke K, Villiger PM, Østensen M.

Swiss Med Wkly. 2012 Jul 18;142:w13644. doi: 10.4414/smw.2012.13644.

17.

Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study.

Mjaavatten MD, van der Heijde DM, Uhlig T, Haugen AJ, Nygaard H, Bjørneboe O, Kvien TK.

J Rheumatol. 2011 Nov;38(11):2336-41. doi: 10.3899/jrheum.110234. Epub 2011 Oct 1.

PMID:
21965645
18.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
19.
20.

Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.

Ma MH, Scott IC, Dahanayake C, Cope AP, Scott DL.

J Rheumatol. 2014 Jul;41(7):1298-303. doi: 10.3899/jrheum.131401.

PMID:
24931951

Supplemental Content

Support Center